Abstract
Background Fabry disease (FD) is an X-linked disorder caused by deleterious variants in GLA. Cardiovascular disease (CVD) causes premature mortality in FD. Hope for aspirin (acetylsalicylic acid, ASA) to reduce CVD risks in FD as primary prevention may have been tempered by the 2018 ARRIVE, ASCEND, and ASPREE clinical trials. It is unclear how new ASA guidance applies to FD patients, who have a high rate of young-onset, small vessel stroke compared with the general population.
Methods Longitudinal data spanning 2007-2023 from patients in the Canadian Fabry Disease Initiative (CFDI) were analyzed retrospectively. Incident stroke and transient ischemic attack (TIA), other CVD events, FD-specific risk factors, and ASA/antiplatelet (“ASA/AP”) prescription before and after 2018 were compared between groups who never had an event (“primary prevention group”) to those who had incident stroke/TIA during the study. Stroke/TIA rates were compared between the sexes, by GLA variant severity, and between the CFDI to Canadian statistics. 10-year atherosclerotic CVD (ASCVD) risk was calculated using the 2013 ACC/AHA risk calculator. ASA/AP prescription rate was compared before and after 2018.
Results Out of 641 patients, 57 had an incident stroke/TIA during the study, and 193 with complete data remained in the primary prevention group. Stroke/TIA rates were significantly higher among male patients (0.026/year) than females (0.0098/year), and higher among patients with severe GLA variants (males: 0.031, females: 0.0096) compared to those with attenuated variants (males: 0.011, females: 0.0088). No patients under 60 years at their incident stroke/TIA had high (≥10%) calculated 10-year ASCVD risk. Fewer patients were prescribed ASA/AP for primary prevention after 2018.
Conclusions There was a high incidence of stroke/TIA in the younger CFDI cohort compared to the general Canadian population, despite low levels of traditional vascular risk factors as represented in 10-year estimated ASCVD risk. Primary prevention use of ASA has declined.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The CFDI is sponsored by the Canadian Fabry Disease Initiative Research Consortium, which receives unrestricted funding from multiple sources, most recently including Takeda Pharmaceuticals, Sanofi Genzyme and Amicus Therapeutics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical research ethics board of the University of British Columbia gave ethical approval for this work (application H17-00574).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Full list of the CFDI investigator group members and locations are detailed in the Supplementary Material.
Data Availability
Summary data produced in the present study are available upon reasonable request to the authors.
Non-standard Abbreviations and Acronyms
- a-gal A
- Alpha-galactosidase A
- AP
- Antiplatelet
- ASA
- Acetylsalicylic acid
- ASCVD
- Atherosclerotic cardiovascular disease
- CABG
- Coronary artery bypass grafting
- CFDI
- Canadian Fabry Disease Initiative
- CT
- Computed tomography
- CVD
- Cardiovascular Disease
- eGFR
- Estimated glomerular filtration rate
- ERT
- Enzyme replacement therapy
- FD
- Fabry disease
- Gb3
- Globotriaosylceramide
- GLA
- Galactosidase alpha
- HF
- Heart failure
- LVMI
- Left ventricular mass index
- Lyso-Gb3
- Globotriaosylsphingosine
- MACE
- Major adverse cardiovascular event
- MI
- Myocardial Infarction
- MRI
- Magnetic resonance imaging
- PCI
- Percutaneous coronary intervention
- TIA
- Transient ischemic attack
- USPSTF
- United States Preventive Service Task Force
